Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. MarketScreener Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FACTBOX-Latest on the worldwide spread of the coronavirus

04/08/2021 | 02:18am EDT

April 8 (Reuters) - The COVAX vaccine facility has delivered nearly 38.4 million doses of COVID-19 vaccines to 102 countries and economies across six continents, six weeks after it began to roll out supplies.

DEATHS AND INFECTIONS

* Eikon users, see COVID-19: MacroVitals https://apac1.apps.cp.thomsonreuters.com/cms/?navid=1592404098 for a case tracker and summary of news.

EUROPE

* Germany's vaccine task force will hold talks with the developers of Russia's Sputnik V shot, including the possibility of setting up more production sites in Germany, a government source told Reuters.

* More than 10 million people in France have now received a first shot of a COVID-19 vaccine, Prime Minister Jean Castex said.

* Italy's government is preparing a new stimulus package worth more than 30 billion euros ($35.62 billion) to support its battered economy, driving up this year's budget deficit, a senior Treasury official said.

AMERICAS

* Brazilian health regulator Anvisa said it has approved the beginning of clinical trials in the country for a new COVID vaccine developed by Canada's Medicago R&D and GlaxoSmithKline.

* Mexican and Brazilian health regulators said they would not limit use of AstraZeneca's shot after Britain's vaccine advisory committee recommended not using it for people under 30.

* The U.S. government will allot nearly 85% less Johnson & Johnson vaccines to states next week, data from Centers for Disease Control and Prevention showed.

ASIA-PACIFIC

* Australia said it now recommends people under 50 should get Pfizer's vaccine in preference to AstraZeneca's shot, a policy shift that it warned would hold up its inoculation campaign.

* India's health minister said the country had more than 43 million vaccine doses in stock or in the pipeline, after many states complained of having to close inoculation centres due to a lack of supplies.

* Indonesia is in talks with China to secure as many as 100 million vaccine doses to plug a gap in deliveries after delays in arrivals of AstraZeneca shots, the health minister said.

* The Philippines suspended use of AstraZeneca's vaccine for people below 60 years of age to investigate reports of blood clots from overseas.

MIDDLE EAST AND AFRICA

* Tunisia approved Johnson & Johnson's vaccine, Health minister Faouzi Mehdi said, and will soon receive 1.5 million doses of the vaccine under an African Union plan.

* The New Development Bank of the BRICS group of nations has approved a second $1 billion loan to South Africa's government to fight the pandemic, the bank said.

* The African Union dropped plans to buy vaccines from the Serum Institute of India and is exploring options with Johnson & Johnson.

* Algeria will start producing Russia's Sputnik V vaccine in September in partnership with Moscow, and part of the production will be intended for African countries.

MEDICAL DEVELOPMENTS

* Moderna's chief medical officer said the company should be able to provide a booster shot for protection against variants by the end of this year.

* The U.S. National Institutes of Health has begun a mid-stage study to determine the risk of allergic reactions to the Moderna and Pfizer vaccines.

ECONOMIC IMPACT

* Stocks in Europe reached record highs, buoyed by optimism in Britain about an easing of lockdown restrictions, while a benign outlook for U.S. interest rates was set to thrust Wall Street to new heights.

* Euro zone bond yields dipped amid uncertainty over the bloc's COVID-19 vaccination programme, while minutes of the European Central Bank's March meeting showed policymakers were ready to reduce bond purchases if conditions allowed.

(Compiled by Veronica Snoj and Sarah Morland; Editing by Gareth Jones/Mark Heinrich)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.27% 7380 Delayed Quote.0.76%
MODERNA, INC. 6.84% 170.81 Delayed Quote.53.03%
SHILPA MEDICARE LIMITED 1.28% 381.25 End-of-day quote.-15.32%
All news about ASTRAZENECA PLC
04/16ASTRAZENECA  : Quebec to deploy sound trucks in Montreal to announce mobile vacc..
AQ
04/16ASTRAZENECA  : Doctors say lowering age cutoff for AstraZeneca vaccine makes sen..
AQ
04/16Consumer Cos Climb On Reopening Optimism -- Consumer Roundup
DJ
04/16Health Care Up After Strong Start to Earnings Season -- Health Care Roundup
DJ
04/16Vaccine Manufacturing Issues Force Moderna to Cut Supplies to Canada, U.K.
DJ
04/16No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cas..
DJ
04/16ASTRAZENECA  : German's IDT to make 10M AstraZeneca vaccine doses in 2021
AQ
04/16ASTRAZENECA  : Covid-19 - Lagos, Kano Lead As Nigeria Vaccinates Over 1m Persons
AQ
04/16MARKET CHATTER : Johnson & Johnson Reportedly Asked Other COVID-19 Vaccine Produ..
MT
04/16ASTRAZENECA  : Australia's Medicine Watchdog Links Woman's Death To AstraZeneca ..
MT
More news
Financials (USD)
Sales 2021 30 805 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 26,1x
Yield 2021 2,79%
Capitalization 134 B 134 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 102,07 $
Spread / Highest target 62,6%
Spread / Average Target 27,0%
Spread / Lowest Target -7,74%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC0.76%133 897
JOHNSON & JOHNSON3.09%422 260
ROCHE HOLDING AG0.16%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-3.73%197 072
MERCK & CO., INC.-5.29%194 049